Digital CBT for Insomnia and Depression

Sponsor
University of Rochester (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05456607
Collaborator
United States Department of Defense (U.S. Fed), University of South Florida (Other), Harvard University (Other), University of California, Irvine (Other)
1,500
1
5
56.9
26.3

Study Details

Study Description

Brief Summary

This study has two primary objectives, each of which addresses critical clinical and research gaps for individuals who have co-occurring insomnia and depression. The first objective is to address whether sequential treatment of insomnia and depression is superior to a single treatment for either depression or for insomnia, and if so, which treatment sequence is optimal. The second objective is to determine if there are heterogeneity of treatment effects; that is, variation in which interventions are best for which individuals, and if so, to develop and individualized intervention rule to better match individuals with the treatment that is most likely to lead to the best outcomes. A large randomized trial will be conducted to meet these objectives.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Cognitive Behavioral Therapy for Insomnia
  • Behavioral: Cognitive Behavioral Therapy for Depression
  • Behavioral: Mood Monitoring
N/A

Detailed Description

Although efficacious behavioral treatments like cognitive behavioral therapy for insomnia (CBT-I) and for depression (CBT-D) exist for insomnia and depression disorders, their impact on co-occurring symptoms can be modest and residual symptoms often remain. In addition, scalable versions of these interventions (like computer accessible or phone app versions) are needed for U.S. military Veterans who lack access to first-line interventions because of rural or other resource-limited environments. Finally, little is known about heterogeneity of treatment effects; that is, variation in which interventions are best for which individuals. This comparative effectiveness trial is designed to develop an an individualized intervention rule to match the right digital intervention to the right person with co-occurring insomnia and depression.

The study will use digital versions of CBT-I and CBT-D found to be efficacious for their intended target. A total of 1,500 participants who are Veterans with both insomnia and depression will be randomized with equal allocation to five study arms: two single interventions (CBT-I or CBT-D); two sequenced interventions (CBT-I+D or CBT-D+I); and a mood monitoring condition that will serve as the control group. Assessments occur at baseline, mid-treatment, post-treatment, at 3-month and 6-month follow-ups. The primary endpoint will be remission of both depression and insomnia at 3 months following the 12 week intervention period. All study activity will be conducted remotely including recruitment, treatment delivery and assessments, so that participants can be recruited nationwide.

The study will estimate average treatment effects on insomnia and depression remission at 3-months post-treatment (primary outcome) and 6-month maintenance of remission as well as treatment response. Significantly higher remission and response rates for sequenced rather than single interventions and lowest for the mood monitoring control condition are expected. Because variation in which interventions are best for which individuals are expected, study investigators will develop and evaluate an individualized intervention rule to determine an optimal approach for each participant in promoting 3-month remission of both disorders. A cutting-edge ensemble machine learning method will be used to do this. In a companion, subsequent trial with a new cohort of 800 participants, the investigators will evaluate whether assigning participants to a treatment condition via the individualized intervention rule is superior to simple randomization that does not consider individual factors in the treatment decision. This subsequent trial will be registered as a separate clinical trial, but will refer back to this current trial.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1500 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Optimizing Digital Behavioral Treatment for Co-occurring Insomnia and Depression
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Sep 30, 2027

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control

Online Mood Monitoring for 12 weeks

Behavioral: Mood Monitoring
The mood monitoring intervention is based on mood tracking principles in broader mood management interventions, but without any psychoeducational content or cognitive-behavioral exercises. Instead, participants will get access to a mobile optimized web app that allows users to enter their mood, tag related events, and view trends over time to raise awareness of how activities influence certain mood states.

Experimental: Single Insomnia Treatment

Cognitive-behavioral therapy for insomnia delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access for 12 weeks.

Behavioral: Cognitive Behavioral Therapy for Insomnia
Cognitive Behavioral Therapy for Insomnia consists of the standard features of this well-established insomnia treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
Other Names:
  • CBT-I
  • Experimental: Single Depression Treatment

    Cognitive-behavioral therapy for depression delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access for 12 weeks.

    Behavioral: Cognitive Behavioral Therapy for Depression
    Cognitive Behavioral Therapy for Depression consists of the standard features of this well-established depression treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
    Other Names:
  • CBT-D
  • Experimental: Sequenced Depression and Insomnia Treatment

    Cognitive-behavioral therapy for depression followed by cognitive-behavioral therapy for insomnia each delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access to the depression treatment only for 4 weeks after which the access to the insomnia treatment is also made available. Total duration of access for 12 weeks.

    Behavioral: Cognitive Behavioral Therapy for Insomnia
    Cognitive Behavioral Therapy for Insomnia consists of the standard features of this well-established insomnia treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
    Other Names:
  • CBT-I
  • Behavioral: Cognitive Behavioral Therapy for Depression
    Cognitive Behavioral Therapy for Depression consists of the standard features of this well-established depression treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
    Other Names:
  • CBT-D
  • Experimental: Sequenced Insomnia and Depression Treatment

    Cognitive-behavioral therapy for insomnia followed by cognitive-behavioral therapy for depression each delivered in a self-managed online format (computer or phone app) with access to a coach. Duration of access to the insomnia treatment only for 4 weeks after which the access to the depression treatment is also made available. Total duration of access for 12 weeks.

    Behavioral: Cognitive Behavioral Therapy for Insomnia
    Cognitive Behavioral Therapy for Insomnia consists of the standard features of this well-established insomnia treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
    Other Names:
  • CBT-I
  • Behavioral: Cognitive Behavioral Therapy for Depression
    Cognitive Behavioral Therapy for Depression consists of the standard features of this well-established depression treatment that will be delivered in this study via a mobile optimized web app. Participants also have access to an intervention coach/guide as needed.
    Other Names:
  • CBT-D
  • Outcome Measures

    Primary Outcome Measures

    1. Dual Remission of Depression and Insomnia [3 Months post-treatment]

      The proportion of participants achieving dual remission in each study arm with Depression Remission defined as a total score of < 5 on the Patient Health Questionnaire (PHQ-9) and Insomnia Remission defined as a total score of < 8 on the Insomnia Severity Index (ISI).

    Secondary Outcome Measures

    1. Depression Response [3 Months post treatment]

      The proportion of participants achieving a Depression treatment response defined as a ≥ 5 point reduction in the total PHQ-9 score

    2. Insomnia Response [3 Months post treatment]

      The proportion of participants achieving an Insomnia treatment response defined as a ≥ 8 point reduction in the total ISI score

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • English-speaking

    • U.S. Military Veterans

    • endorse depression (Patient Health Questionnaire-depression score > 10)

    • endorse insomnia (Insomnia Severity Index score > 10).

    Exclusion Criteria are limited in accordance with real world effectiveness trials, but will include:

    • pregnancy

    • history of bipolar disorder

    • history of psychosis

    • current use of anti-psychotic medications or mood stabilizers (e.g., lithium)

    • current suicidal ideation with active intent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Rochester Sleep Research Laboratory Rochester New York United States 14642

    Sponsors and Collaborators

    • University of Rochester
    • United States Department of Defense
    • University of South Florida
    • Harvard University
    • University of California, Irvine

    Investigators

    • Principal Investigator: Wilfred Pigeon, PhD, University of Rochester

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Wilfred Pigeon, PhD, Professor of Psychiatry, University of Rochester
    ClinicalTrials.gov Identifier:
    NCT05456607
    Other Study ID Numbers:
    • STUDY00007379
    First Posted:
    Jul 13, 2022
    Last Update Posted:
    Jul 13, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Wilfred Pigeon, PhD, Professor of Psychiatry, University of Rochester
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 13, 2022